van Dam, P A ✱; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Edegem
Debie, Yana ✱; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Santé publique vétérinaire ; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Edegem
Teuwen, L; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem
Verbruggen, L; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem
Vanhoutte, G; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem
Peeters, B; Department of Laboratory Medicine, Antwerp University Hospital, Edegem
Croes, L; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Edegem, GeIntegreerd Kankercentrum Gent (IKG), AZ Maria Middelares, Ghent, Belgium
Vulsteke, C; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Edegem, GeIntegreerd Kankercentrum Gent (IKG), AZ Maria Middelares, Ghent, Belgium
Anguille, S; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem
Vandamme, T; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Edegem
Peeters, M; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Edegem. Electronic address: marc.peeters@uza.be
✱ These authors have contributed equally to this work.
Language :
English
Title :
Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients.
We are grateful to the B-VOICE and Tri-VOICE plus study teams for patient inclusion and sample collection. They were not compensated for their contribution. We also want to thank all our patients for study participation. None declared. The authors have declared no conflicts of interest.
Garassino, M.C., Vyas, M., de Vries, E.G.E., et al. The ESMO call to action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate. Ann Oncol 32:5 (2021), 579–581.
Peeters, M., Verbruggen, L., Teuwen, L., et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open, 6(5), 2021, 100274.
Fendler, A., Shepherd, S.T.C., Au, L., et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer 2 (2021), 1321–1337.
Debie, Y., Vandamme, T., Goossens, M.E., van Dam, P.A., Peeters, M., Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in cancer patients. Eur J Cancer 163 (2022), 177–179.
Gounant, V., Ferré, V.M., Soussi, G., et al. Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol 17:2 (2022), 239–251.
